Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PIP4K2C | Q8TBX8 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL814317 | 0.99 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Bromide SCHEMBL816797 | 0.94 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Hydrochloric Acid SCHEMBL812571 | 0.93 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Hydrochloric Acid SCHEMBL814537 | 0.93 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Bromide SCHEMBL813601 | 0.93 | MAPT (0.40) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Bromide SCHEMBL813757 | 0.93 | PIP4K2C (0.40) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Hydrochloric Acid SCHEMBL812428 | 0.92 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Bromide SCHEMBL813162 | 0.92 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Hydrochloric Acid SCHEMBL812997 | 0.91 | MAPT (0.41) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C | |
| Hydrochloric Acid SCHEMBL812715 | 0.91 | MAPT (0.41) | SMN1; SMN2MAPTLIN28ATDP1PIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058372-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20080319147-A1 | Catalyst Composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-12-25 | — | — | US | disclosed |
| US-7371803-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070066776-A1 | Catalyst composition II | SOLAN GREGORY A | 2007-03-22 | — | — | US | disclosed |
| US-7189791-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1641842-A2 | POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND | Exxonmobil Chemical Patents Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004106390-A2 | POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266961-A1 | Catalyst composition II | MLX, CBX2, BMX | ACHE 3557/4885SMN1; SMN2 1110/4885MAPT 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.